Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) Director Mark W. Parrish sold 12,000 shares of the firm's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now directly owns 58,427 shares of the company's stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Omnicell Price Performance
Shares of NASDAQ:OMCL opened at $45.96 on Friday. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74. The business's 50 day simple moving average is $45.25 and its 200 day simple moving average is $38.90.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on OMCL. Wells Fargo & Company upped their target price on Omnicell from $30.00 to $41.00 and gave the stock an "equal weight" rating in a report on Monday, October 14th. JPMorgan Chase & Co. upped their price objective on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Bank of America reissued a "neutral" rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays lifted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. Finally, StockNews.com downgraded shares of Omnicell from a "buy" rating to a "hold" rating in a report on Tuesday. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Omnicell presently has an average rating of "Hold" and an average price target of $52.00.
AI Crypto Tool Could Send One Coin SOARING…
From Crypto 101 Media | Ad
The #1 AI Coin to Buy
Rapid growth predicted for little-known AI crypto project
Discover our #1 crypto pick before it's too late.
View Our Latest Analysis on Omnicell
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its stake in Omnicell by 61.3% in the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company's stock valued at $16,240,000 after buying an additional 228,093 shares in the last quarter. Pier Capital LLC acquired a new stake in shares of Omnicell during the third quarter valued at about $5,859,000. Federated Hermes Inc. boosted its position in Omnicell by 1,113.6% during the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company's stock worth $26,830,000 after buying an additional 909,480 shares during the period. Royce & Associates LP bought a new position in shares of Omnicell during the third quarter valued at $811,000. Finally, Intech Investment Management LLC acquired a new position in shares of Omnicell in the 3rd quarter valued at about $753,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.
Omnicell Company Profile
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
